Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 677-682

  Devor, Eric J ^a   de Mik, Jillian N ^a   Ramachandran, Shyam ^a   Goodheart, Michael J ^a,b   Leslie, Kimberly K ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Chromosome 14q32; MicroRNA; Uterine carcinosarcoma

Indexed keywords

DKL1 PROTEIN; GTL2 PROTEIN; MICRORNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOSARCOMA; CHROMOSOME 14Q; CHROMOSOME 14Q32; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; GENOME IMPRINTING; GLOBAL CHROMOSOME DYSREGULATION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; UTERINE CARCINOSARCOMA;

EID: 84857011633     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.458     Document Type: Article

References (31)

1. D'Angelo E and Prat J: Uterine sarcomas: A review. Gynecol Oncol 116: 131-139, 2010.
2. Evans HL, Chawla SP, Simpson C and Finn KP: Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases with emphasis on diagnostic criteria and prognostic factors. Cancer 62: 2239-2247, 1988.
3. Kernochan LE and Garcia RL: Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: Advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 7: 550-557, 2009.
4. Zelmanowicz A, Hildesheim A, Sherman ME, et al: Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 69: 253-257, 1998.
5. Silverberg SG, Major FJ, Blessing JA, et al: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9: 1-19, 1990.
6. Sreenan JJ and Hart WR: A pathologic study of 29 metastatic tumors: Further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 19: 666-674, 1995.
7. Jin Z, Ogata S, Tamura G, et al: Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: A genetic study with special reference to histogenesis. Int J Gynecol Pathol 22: 368-373, 2003.
8. Wada H, Enomoto T, Fujita M, et al: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 57: 5379-5385, 1997.
9. Abeln EC, Smit VT, Wessels JW, et al: Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumors. J Pathol 183: 424-431, 1997.
10. Fujii H, Yoshida M, Gong ZX, et al: Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 60: 114-120, 2000.
11. Taylor NP, Zighelboim I, Huettner PC, et al: DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 19: 1333-1338, 2006.
12. Melo SA and Esteller M: Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett 585: 2087-2099, 2011.
13. Rovira C, Güida MC and Cayota A: MicroRNAs and other small silencing RNAs in cancer. IUBMB Life 62: 859-868, 2010.
14. Kircher M, Bock C and Paulsen M: Structural conservation versus functional divergence of maternally expressed microRNAs in the Dlk1/Gtl2 imprinting region. BMC Genomics 9: 346, 2008.
15. Guens E, De Temmerman N, Hilven P, et al: Methylation analysis of the intergenic differentially methylated region of DLK1-GTL2 in human. Eur J Hum Genet 15: 352-361, 2007.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25: 402-408, 2001.
17. Guo W, Sarkar SK and Peddada SD: Controlling false discoveries in multidimensional directional decisions, with applications to gene expression data on ordered categories. Biometrics 66: 485-492, 2010.
18. Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S and Leslie KK: microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep 26: 995-1002, 2011.
19. Ratner ES, Tuck D, Richter C, et al: MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol 118: 251-257, 2010.
20. Castilla MA, Moreno-Bueno G, Romero-Perez L, et al: Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 223: 72-80, 2011.
21. Sengupta S, den Boon JA, Chen IH, et al: MicroRNA 29c is down-regulated in nasalpharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105: 5874-5878, 2008.
22. Salvi A, Sabelli C, Moncini S, et al: MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J 276: 2966-2982, 2009.
23. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK and Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066, 2009.
24. Gregory P, Bert A, Paterson E, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008.
25. Vrba L, Jensen TJ, Garbe, JC, et al: Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 5: e8697, 2010.
26. Dixon-McIver A, East P, Mein CA, et al: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leulaemia. PLoS ONE 3: e2141, 2008.
27. Haller F, von Heydebreck A, Zhang JD, et al: Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J Pathol 220: 71-86, 2010.
28. Micci F, Tiexeira MR, Haugom L, Abeler VM and Heim S: Genomic aberrations in carcinomas of the uterine corpus. Genes Chrom Cancer 40: 229-246, 2004.
29. Salvesen HB, Carter SL, Mannelqvist M, et al: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106: 4834-4839, 2009.
30. Seitz H, Royo H, Bortolin M-L, et al: A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 14: 1741-1748, 2004.
31. Sánchez-Solana B, Nueda ML, Ruvira MD, et al: The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities. Biochim Biophys Acta 1813: 1153-1164, 2011.